MetaVia names Sarah Browne chief medical officer
MTVA•MetaVia named Sarah Browne chief medical officer, effective Oct. 12, 2026. Browne previously led clinical development at Altimmune, advancing pemvidutide through Phase 2 and setting Phase 3 strategy.
1. Appointment details
MetaVia named Sarah Browne chief medical officer, effective Oct. 12, 2026. She was a clinical development consultant at Soufflé Therapeutics, advising on development planning and regulatory strategy, and previously led clinical development at Altimmune.
2. Prior development work
At Altimmune, Browne advanced pemvidutide through Phase 2 and set Phase 3 strategy.
